Patents by Inventor Hemant Khanna

Hemant Khanna has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220233720
    Abstract: Aspects of the disclosure relate to compositions and methods useful for treating ocular ciliopathies, for example Leber congenital amaurosis (LCA). In some embodiments, the disclosure provides isolated nucleic acids comprising a transgene encoding a CEP290 protein fragment, and methods of treating ocular ciliopathies using the same.
    Type: Application
    Filed: May 19, 2020
    Publication date: July 28, 2022
    Applicant: University of Massachusetts
    Inventors: Guangping Gao, Hemant Khanna
  • Publication number: 20220202959
    Abstract: Aspects of the disclosure relate to compositions and methods useful for delivering minigenes to a subject. Accordingly, the disclosure is based, in part, on isolated nucleic acids and gene therapy vectors, such as viral (e.g., rAAV) vectors, comprising one or more gene fragments encoding a therapeutic gene product, such as a protein or peptide (e.g., a minigene). In some embodiments, the disclosure relates to gene therapy vectors encoding a USH2A protein (e.g., the gene product of USH2A gene) or a portion thereof. In some embodiments, compositions described by the disclosure are useful for treating diseases associated with mutations in the USH2A gene, for example Usher Syndrome.
    Type: Application
    Filed: April 16, 2020
    Publication date: June 30, 2022
    Applicant: University of Massachusetts
    Inventor: Hemant Khanna
  • Publication number: 20220177539
    Abstract: Aspects of the disclosure relate to compositions and methods useful for delivering minigenes to a subject. Accordingly, the disclosure is based, in part, on isolated nucleic acids and gene therapy vectors, such as viral (e.g., rAAV) vectors, comprising one or more gene fragments encoding a therapeutic gene product, such as a protein or peptide (e.g., a minigene). In some embodiments, the disclosure relates to gene therapy vectors encoding a ABCA4 protein (e.g., the gene product of ABCA4 gene) or a portion thereof. In some embodiments, compositions described by the disclosure are useful for treating diseases associated with mutations in the ABCA4 gene, for example Stargardt disease.
    Type: Application
    Filed: April 16, 2020
    Publication date: June 9, 2022
    Applicant: University of Massachusetts
    Inventor: Hemant Khanna
  • Publication number: 20220175967
    Abstract: Aspects of the disclosure relate to compositions and methods useful for delivering minigenes to a subject. Accordingly, the disclosure is based, in part, on isolated nucleic acids and gene therapy vectors, such as viral (e.g., rAAV) vectors, comprising one or more gene fragments encoding a therapeutic gene product, such as a protein or peptide (e.g. a minigene). In some embodiments, the disclosure relates to gene therapy vectors encoding a USH1B protein (e.g. the gene product of USH1B, also referred to as MY07A) or a portion thereof. In some embodiments, compositions described by the disclosure are useful for treating diseases associated with mutations in the USH1B (MY07A) gene, for example Usher Syndrome.
    Type: Application
    Filed: April 16, 2020
    Publication date: June 9, 2022
    Applicant: University of Massachusetts
    Inventor: Hemant Khanna
  • Publication number: 20220054655
    Abstract: Aspects of the disclosure relate to isolated nucleic acids, rAAVs, and compositions configured to express an oxidative stress resistance protein (e.g., OXR1, NCOA7-AS, NCOA7-FL). In some embodiments, the compositions of the disclosure are useful for treatment of diseases or conditions associated with oxidative stress, for example neuronal degeneration.
    Type: Application
    Filed: February 21, 2020
    Publication date: February 24, 2022
    Applicant: University of Massachusetts
    Inventors: Michael R. Volkert, Hemant Khanna
  • Publication number: 20200056204
    Abstract: Aspects of the disclosure relate to compositions and methods useful for treating ocular ciliopathies, for example Leber congenital amaurosis (LCA). In some embodiments, the disclosure provides isolated nucleic acids comprising a transgene encoding a CEP290 protein fragment, and methods of treating ocular ciliopathies using the same.
    Type: Application
    Filed: April 5, 2018
    Publication date: February 20, 2020
    Applicant: University of Massachusetts
    Inventors: Guangping Gao, Hemant Khanna
  • Patent number: 7838231
    Abstract: The present invention relates to Nephronophthisis, in particular to the NPHP6 protein (nephrocystin-6) and nucleic acids encoding the NPHP6 protein. The present invention also provides assays for the detection of NPHP6, and assays for detecting NPHP6 polymorphisms and mutations associated with disease states.
    Type: Grant
    Filed: April 5, 2007
    Date of Patent: November 23, 2010
    Assignee: The Regents of the University of Michigan
    Inventors: Friedhelm Hidebrandt, Edgar A. Otto, Hemant Khanna, Anand Swaroop
  • Patent number: 7517648
    Abstract: The present invention relates to Nephronophthisis, in particular to the NPHP5 protein (nephrocystin-5) and nucleic acids encoding the NPHP5 protein. The present invention also provides assays for the detection of NPHP5 polymorphisms and mutations associated with disease states.
    Type: Grant
    Filed: February 18, 2005
    Date of Patent: April 14, 2009
    Assignee: The Regents of the University of Michigan
    Inventors: Friedhelm Hildebrandt, Edgar A. Otto, Hemant Khanna, Anand Swaroop
  • Publication number: 20080044831
    Abstract: The present invention relates to Nephronophthisis, in particular to the NPHP6 protein (nephrocystin-6) and nucleic acids encoding the NPHP6 protein. The present invention also provides assays for the detection of NPHP6, and assays for detecting NPHP6 polymorphisms and mutations associated with disease states.
    Type: Application
    Filed: April 5, 2007
    Publication date: February 21, 2008
    Applicant: The Regents of the University of Michigan
    Inventors: Friedhelm Hidebrandt, Edgar Otto, Hemant Khanna, Anand Swaroop
  • Patent number: 7282580
    Abstract: The present invention relates to a novel molecule useful for anthrax toxin inhibition in vivo and also provides a method for in vivo inhibition of anthrax toxin action using the new molecule.
    Type: Grant
    Filed: February 17, 2004
    Date of Patent: October 16, 2007
    Assignee: Council of Scientific and Industrial Research
    Inventors: Yogendra Singh, Hemant Khanna
  • Publication number: 20050214864
    Abstract: The present invention relates to Nephronophthisis, in particular to the NPHP5 protein (nephrocystin-5) and nucleic acids encoding the NPHP5 protein. The present invention also provides assays for the detection of NPHP5 polymorphisms and mutations associated with disease states.
    Type: Application
    Filed: February 18, 2005
    Publication date: September 29, 2005
    Applicant: The Regents of the University of Michigan
    Inventors: Friedhelm Hildebrandt, Edgar Otto, Hemant Khanna, Anand Swaroop
  • Publication number: 20040235136
    Abstract: The present invention relates to a novel molecule useful for anthrax toxin inhibition in vivo and also provides a method for in vivo inhibition of anthrax toxin action using the new molecule.
    Type: Application
    Filed: February 17, 2004
    Publication date: November 25, 2004
    Inventors: Yogendra Singh, Hemant Khanna